#Ireland #Dublin #Healthcare Conference #Investor Relations #Jazz Pharmaceuticals

Jazz Pharmaceuticals to Participate in Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is preparing for an active presence at multiple investor conferences in the upcoming months. The company has announced that its management team will engage in discussions at events that cater to healthcare investors. This initiative is designed to deepen connections with the investment community and share insights into the company’s vision and innovations.

Conference Schedule

The schedule for Jazz Pharmaceuticals includes:

• - Jefferies London Global Healthcare Conference on November 17, 2026, at 8:00 AM ET.
• - Piper Sandler’s 38th Annual Healthcare Conference on December 2, 2026, at 8:00 AM ET.
• - Citi’s 2026 Global Healthcare Conference on December 2, 2026, at 3:00 PM ET.

These forums will allow Jazz Pharmaceuticals to showcase its progress and strategic direction in developing therapies that address significant unmet medical needs. The company is particularly focused on rare diseases and is dedicated to providing life-changing medications for patients who often have limited or no treatment options.

Accessibility of Information

For those interested in following along, Jazz Pharmaceuticals will provide audio webcasts of the fireside chats through the Investors section of their official website. You can access the presentations at Jazz Pharmaceuticals Investor Events. Additionally, a replay of these webcasts will be archived for 30 days after the events for those unable to attend live.

About Jazz Pharmaceuticals

Headquartered in Dublin, Jazz Pharmaceuticals is a global biopharmaceutical company committed to innovative healthcare solutions that enhance the lives of patients and their families. The company has a diverse portfolio of medicines targeting areas such as epilepsy, cancer, and sleep disorders, demonstrating their commitment to research and development in meeting patients’ needs worldwide.

With a strong patient-focused mission and a science-driven approach, Jazz continues to work on pioneering advancements in the healthcare sector. The company operates across multiple countries with state-of-the-art laboratories and manufacturing facilities, ensuring that they are well-equipped to serve patients globally.

For further information, you can visit their website at www.jazzpharmaceuticals.com.

Conclusion

Engaging with investors is an essential aspect of Jazz Pharmaceuticals' strategy, as it enhances transparency and fosters trust within the community. As the company prepares for these key dates, stakeholders and interested parties are encouraged to participate and gain insights into Jazz’s promising future and the vital role they play in addressing today's healthcare challenges.